Kiora Enterprise Value vs Tangible Asset Value Analysis
KPRX Stock | USD 0.51 0.04 7.27% |
Kiora Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kiora Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kiora Pharmaceuticals is a good investment. Please check the relationship between Kiora Pharmaceuticals Enterprise Value and its Tangible Asset Value accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.
Enterprise Value vs Tangible Asset Value
Enterprise Value vs Tangible Asset Value Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kiora Pharmaceuticals Enterprise Value account and Tangible Asset Value. At this time, the significance of the direction appears to have no relationship.
The correlation between Kiora Pharmaceuticals' Enterprise Value and Tangible Asset Value is 0.0. Overlapping area represents the amount of variation of Enterprise Value that can explain the historical movement of Tangible Asset Value in the same time period over historical financial statements of Kiora Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kiora Pharmaceuticals' Enterprise Value and Tangible Asset Value is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Enterprise Value of Kiora Pharmaceuticals are associated (or correlated) with its Tangible Asset Value. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Tangible Asset Value has no effect on the direction of Enterprise Value i.e., Kiora Pharmaceuticals' Enterprise Value and Tangible Asset Value go up and down completely randomly.
Correlation Coefficient | 0.0 |
Relationship Direction | Flat |
Relationship Strength | Insignificant |
Enterprise Value
Enterprise Value (or EV) is usually referred to as Kiora Pharmaceuticals theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Kiora Pharmaceuticals debt, but would also pocket its cash. Enterprise Value is more accurate representation of Kiora Pharmaceuticals value than its market capitalization because it takes into account all of Kiora Pharmaceuticals existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.Tangible Asset Value
The total value of a company's physical, tangible assets, excluding intangible assets like patents and trademarks.Most indicators from Kiora Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiora Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.At this time, Kiora Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 94.8 K in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.02) in 2024.
Kiora Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Kiora Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kiora Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.1M | 15.2M | 18.1M | 18.7M | 13.7M | 11.7M | |
Short Long Term Debt Total | 83.9K | 362.1K | 209.4K | 105.8K | 106.9K | 101.5K | |
Other Current Liab | 1.1M | 1.3M | 1.3M | 2.2M | 1.4M | 1.3M | |
Total Current Liabilities | 1.4M | 1.8M | 1.6M | 3.3M | 1.6M | 3.2M | |
Total Stockholder Equity | 6.6M | 7.0M | 9.2M | 11.4M | 6.1M | 6.4M | |
Property Plant And Equipment Net | 16.8K | 30.6K | 283.4K | 172.2K | 115.0K | 76.8K | |
Net Debt | (3.7M) | (823.6K) | (7.6M) | (5.9M) | (2.3M) | (2.5M) | |
Retained Earnings | (100.2M) | (108.3M) | (124.7M) | (134.5M) | (147.0M) | (154.3M) | |
Accounts Payable | 210.3K | 434.8K | 160.6K | 1.0M | 206.3K | 195.9K | |
Cash | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.7M | |
Non Current Assets Total | 5.8M | 13.3M | 9.1M | 11.0M | 9.0M | 6.1M | |
Non Currrent Assets Other | 114.4K | 102.1K | 88.0K | 82.3K | 40.8K | 38.7K | |
Cash And Short Term Investments | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.7M | |
Net Receivables | 4.9K | 91.0K | 529.6K | 1.4M | 2.0M | 2.2M | |
Common Stock Shares Outstanding | 79.5K | 114.8K | 241.1K | 732.3K | 4.8M | 5.1M | |
Liabilities And Stockholders Equity | 10.1M | 15.2M | 18.1M | 18.7M | 13.7M | 11.7M | |
Non Current Liabilities Total | 2.1M | 6.4M | 7.2M | 4.0M | 6.0M | 10.2M | |
Other Current Assets | 542.7K | 533.5K | 606.5K | 343.1K | 233.4K | 368.7K | |
Other Stockholder Equity | 106.7M | 115.3M | 133.9M | 146.0M | 153.2M | 93.1M | |
Total Liab | 3.5M | 8.2M | 8.8M | 7.3M | 7.6M | 12.5M | |
Total Current Assets | 4.3M | 1.8M | 9.0M | 7.7M | 4.7M | 5.6M | |
Accumulated Other Comprehensive Income | 139.5K | (802.0) | (86.4K) | (182.7K) | (182.8K) | (173.7K) | |
Short Term Debt | 83.9K | 48.3K | 118.8K | 105.8K | 47.1K | 44.7K | |
Common Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 101.9K | |
Intangible Assets | 4.1M | 9.7M | 8.7M | 10.7M | 8.8M | 7.9M | |
Other Liab | 1.5M | 2.1M | 6.1M | 7.1M | 8.2M | 8.6M | |
Net Tangible Assets | 7.2M | 4.9M | 3.3M | 9.1M | 10.4M | 10.9M | |
Capital Lease Obligations | 83.9K | 83.9K | 209.4K | 105.8K | 106.9K | 96.0K | |
Net Invested Capital | 6.6M | 7.3M | 9.2M | 11.4M | 6.1M | 7.5M | |
Non Current Liabilities Other | 1.7M | 5.3M | 6.5M | 3.3M | 5.1M | 3.8M | |
Net Working Capital | 2.9M | 37.8K | 7.4M | 4.4M | 3.1M | 2.5M | |
Property Plant Equipment | 43.5K | 16.8K | 30.6K | 283.4K | 325.9K | 342.2K | |
Capital Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 100.8K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Kiora Stock analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 0.002 | Return On Assets (0.34) | Return On Equity (1.43) |
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiora Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.